Enhancement of anti-tumor immune response

Enhancement of anti-tumor immune response" is not a specific molecule, receptor, enzyme, or other distinct molecular therapeutic target. Instead, it is a *therapeutic strategy* or biological process that encompasses numerous molecular mechanisms and interventions aimed at boosting the immune system's ability to recognize and eradicate tumor cells. This approach includes, but is not limited to, immune checkpoint blockade (e.g., PD-1/PD-L1, CTLA-4 inhibitors), modulation of tumor antigen presentation, use of cancer vaccines, adoptive cellular therapies, and agents or techniques that alter immune signaling pathways or disrupt tumor-induced immunosuppression[2][4][5]. Because it refers to a process rather than to a defined molecular entity, this term is not considered a canonical therapeutic target, and its use in this context is incorrect.

A therapeutic strategy encompassing numerous molecular mechanisms and interventions aimed at boosting the immune system's ability to recognize and eradicate tumor cells. This includes, but is not limited to, immune checkpoint blockade, modulation of tumor antigen presentation, use of cancer vaccines, adoptive cellular therapies, and agents or techniques that alter immune signaling pathways or disrupt tumor-induced immunosuppression.